- Patients with NSCLC who have poor performance status (PS) when they initiate immune checkpoint inhibitors (ICIs) have significantly worse outcomes than those with better PS.
Why this matters
- These findings suggest that clinical trials, which have largely excluded patients with poor PS, may not be generalizable to all patients.
- They also suggest that clinicians should consider whether to recommend ICI treatment for advanced NSCLC with poor PS.
- 237 patients with NSCLC received ICIs.
- Median follow-up, 37 months.
- Funding not disclosed.
- 35.4% had poor PS (Eastern Cooperative Oncology Group PS ≥2).
- Median ICI treatment was significantly shorter in patients with poor PS compared with those with PS 0 or 1:
- 37 days vs 119 days (P<.0001>
- Compared with patients with PS ≥2, those with PS 0 or 1 had significantly better median:
- PFS: 3.4 vs 1.7 months (P<.0001>
- OS: 14.3 vs 4.5 months (P<.0001>
- Adjusted HR, 2.37 (95% CI, 1.71-3.30).
- 58.3% vs 40.7% (P=.021).
- Single-center, retrospective study.